SANTA MONICA, Calif., July 9 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board:
CBAI -
News), the umbilical cord blood stem cell preservation company (
http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, today said that Matthew Schissler, CEO, was interviewed about the Company's achievements and future strategies by Francis Gaskins, a financial analyst.
The complete interview is available at http://www.stoxrox.com/cbai-7-8-08-b.mp3 .
Mr. Schissler in the interview said the Company's a.bourkas Co. United subsidiary in Greece will expand into Germany in August. "Europe is ahead of the U.S. in umbilical cord blood storage, with up to 10 percent of the families in Greece participating, and we envision similar results in Germany," Cord Blood America's CEO said.
Mr. Schissler made the point that the recent financial vehicle, established for the Company and detailed in an 8-K filing, will allow the Company options in using non-toxic equity for growth, expansion and reduction of debt.
Specifically, Mr. Schissler stressed that CBAI will move forward with accelerated organic growth and an aggressive acquisition strategy over the next two years. "We are close to running cash flow positive," Mr. Schissler said. He also stressed an increased emphasis on the Company's successful practice of using insurance partners to expand its business to other parts of the country.
The stem cells from the umbilical cord are a perfect match for later transplant purposes and it is so important that families understand this is a one-in-a-lifetime opportunity for the child, Cord Blood America's CEO said.
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), visit our website at http://www.corcell.com. For investor information, visit http://www.cordblood-america.com.
CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com
